Objective: To evaluate the efficacy and safety of Zhumian Tang formula granules combined with eszopiclone for treating poor sleep quality.
Methods: This multi-center, dynamic block-randomized, parallel-group superiority clinical trial included 130 patients. The combined treatment group received Zhumian Tang formula granules combined with eszopiclone treatment, and the control group received eszopiclone treatment only. The group allocation ratio was 1∶1. The duration of treatment was 2 weeks. Participants were asked to complete questionnaires before treatment, after 1 week of the intervention, after 2 weeks of the intervention, and at the follow-up on week 3. The primary outcomes were the Pittsburgh Sleep Quality Index (PSQI) score and the total effective rate of treatment. The secondary outcome was the rate of adverse effects.
Results: Compared with the eszopiclone treatment group, the PSQI score of the combined treatment group was significantly lower after 2 weeks of the intervention (6.98 8.26, 0.05). However, there was no significant difference in the mean PSQI score after 1 week of the intervention (9.89 9.15, 0.124). After the follow-up on week 3, the PSQI score of the combined treatment group remained significantly lower than that of the eszopiclone treatment group (6.12 8.31, 0.001). The total effective rates of treatment of the combined group and the eszopiclone group were 36.92% 35.38% ( 0.033, 0.855) after 1 week of the intervention, 83.08% 58.46% ( 9.519, 0.05) after 2 weeks of the intervention, and 83.08% 61.54% ( 7.530, 0.05) and after the follow-up on week 3, respectively. There was no significant difference in the overall rate of adverse reactions between the combined and eszopiclone treatment groups (21.53% 31.8%, 0.318).
Conclusion: The combination of Zhumian Tang formula granules with eszopiclone was found to be safe and more effective in improving sleep quality than eszopiclone alone. Traditional Chinese medicine can enhance the effectiveness of Western medicine in the treatment of insomnia.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774717 | PMC |
http://dx.doi.org/10.19852/j.cnki.jtcm.2024.01.002 | DOI Listing |
Clin Neuropsychiatry
October 2024
Department of Surgical, Medical and Molecular Pathology, Critical and Care Medicine, University of Pisa, Pisa, Italy, Department of Neuroscience, Azienda Ospedaliera Universitaria Pisana (AUOP), Pisa, Italy.
Objective: Insomnia can be a contributing factor, a comorbid disorder, or a transdiagnostic element to several mental disorders, including mood disorders (MDs). A recent meta-analysis has already shown the effectiveness of cognitive behavioral treatment (CBT) for insomnia that is comorbid with MDs. This work aimed to systematically review data on pharmacological insomnia treatment in the context of MDS.
View Article and Find Full Text PDFExpert Opin Pharmacother
November 2024
Faculty of Medicine, Transilvania University of Braşov, Brașov, Romania.
Ann Am Thorac Soc
November 2024
University of California San Diego, Division of Pulmonary, Critical Care and Sleep Medicine, La Jolla, California, United States.
Introduction: Acetazolamide, eszopiclone, and venlafaxine may target different underlying mechanisms of obstructive sleep apnea (OSA) and individually may partially improve OSA severity in select patients. We tested whether acetazolamide+eszopiclone (DualRx) improves OSA severity. We further explored whether addition of venlafaxine (TripleRx) improves OSA in patients who do not fully respond to DualRx.
View Article and Find Full Text PDFClin Psychol Psychother
November 2024
The First Department of Rehabilitation, The Second Hospital of Hebei Medical University, Shijiazhuang City, China.
Objective: This study aimed to investigate the efficacy of mindfulness meditation on sleep quality and negative emotions in patients with stroke with concurrent coronary heart disease.
Methods: This study was a randomised controlled trial. A total of 72 patients with stroke with concurrent coronary heart disease were randomly divided into an observation group and a control group, with 36 patients in each group.
BMC Gastroenterol
October 2024
Department of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!